Findings from CooperVision’s clinical trial for its MiSight 1day contact lens were presented at the American Academy of Optometry’s annual meeting in Boston.

In its seventh year, participants were transitioned from MiSight to a single vision contact lens to evaluate if treatment gains would be retained.

Myopic progressions only occurred at anticipated ‘age normal’ levels and not at an accelerated ‘catch up’ rate that would offset prior slowing, which CooperVision said indicated no rebound effect.

Paul Chamberlain, the study’s principal investigator, said: ‘Our unparalleled research clearly illustrates the tremendous potential of MiSight 1day for children of different ages and with different levels of myopia, regardless of when they start treatment.’